Launch the RSV vaccine commercially for older adults
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 May 2023
- Due
- 31 Dec 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company continues to expect a 2024 launch of its RSV vaccine”
What we found
Evidence strength A What the grades mean
A later 10-Q states Moderna launched commercial sales of its RSV vaccine in Q3 2024, before the 2024 year-end deadline. The 10-K also reports 2024 RSV net product sales.
-
A Moderna 10-K filed 2025-02-21
“The RSV vaccine was approved by the FDA in May 2024 for adults aged 60 years and older.” ✓ confirmed on the page
-
A Moderna 10-Q filed 2025-05-01
“We launched commercial sales of our RSV vaccine in the third quarter of 2024.” ✓ confirmed on the page
Market reaction: the shares moved -4.1% against the S&P 500 over the three sessions around the disclosure (30 Apr 2025 to 5 May 2025). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- RSV vaccine commercial launch for older adults
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-MRNA-006202 · Corrections policy